XBD173

Phase 2Small molecule

Novartis

XBD173 is one of 51 small molecule programs targeting Cerebral Small Vessel Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral Small Vessel DiseaseActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

PAHEnrolling by invitation

Cerebral Small Vessel DiseasePreclinical

Active, not recruiting

Generalized Anxiety DisorderPhase 2

Active, not recruiting

PAHPhase 1

Enrolling by invitation

Competition

Competitive Landscape

82 competitors in Generalized Anxiety Disorder

#DrugCompanyPhaseTrials

Brintellix

Takeda

Phase 3

4 2

Viibryd

AbbVie

Phase 3

2 3

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

5 4

PD 0360324

Pfizer

Phase 3

7 5

Risperdal

WWim Janssens

Phase 3

2 6

Effexor

WWyeth-Lederle Vaccines

Phase 3

2 7

Quetiapine XR

AstraZeneca

Phase 3

2 8

Lu AF95245

Lundbeck

Phase 3

1 9

Venlafaxine XR

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

3 10

Endari

EEmmaus Medical, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Resistance

NCT06035861

Q2 2028

N/ARecruiting

Cerebral Small Vessel Disease

NCT06643013

Q3 2028

Phase 2Recruiting

Study completion

NCT07682233

Clinical

Trials by Indication[1]

PET1 trial

Reproducibility of the 11C-PBR28 PET Signal

Withdrawn·IImperial College London·N/A·NCT02086240

Resistance1 trial

Endothelial Cell Activation and Total Pulmonary Resistance in PAH

Not yet recruiting·IImperial College London·N/A·NCT06035861·6 enrolled

Generalized Anxiety Disorder1 trial

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Completed· Novartis logo

Novartis·Phase 2·NCT00108836·400 enrolled

Cerebral Small Vessel Disease1 trial

Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease

Recruiting·IImperial College London·N/A·NCT06643013·106 enrolled

PAH1 trial

Investigating the Relationship Between Endothelial Cell Activation and Total Pulmonary Resistance in Pulmonary Artery Hypertension (PAH)

Enrolling by invitation·IImperial College London·Phase 1·NCT07697183·6 enrolled

1 more indication

Unspecified4 trials

TSPO Occupancy in the Human Lung

Enrolling by invitation·IImperial College London·N/A·NCT07362290·16 enrolled

Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

Recruiting·IImperial College London·N/A·NCT03850301·44 enrolled

TSPO Modulation in AD

Enrolling by invitation·IImperial College London·Phase 2·NCT07191821·51 enrolled

Show 1 more trial

An Experimental Medicine Study to Investigate the Role of the 18 kiloDalton Translocator Protein in Glucose Metabolism

Recruiting·IImperial College London·Phase 2·NCT07682233·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for XBD173. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XBD173 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XBD173. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

XBD173

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q3 2028

Trials by Indication[1]

PET1 trial

Resistance1 trial

Generalized Anxiety Disorder1 trial

Cerebral Small Vessel Disease1 trial

PAH1 trial

Unspecified4 trials

References

Drug Info

Quick Facts

Related News